Kristina Jenei

Jul 12, 2024 | drugdevletter.com | Kristina Jenei |Vinay Prasad

Is speed the only thing that’s important when approving new cancer drugs? Some people would argue yes, slow approvals harm patients. You will remember that this was the case with antiretrovirals in the early 1990s and the reason the accelerated approval program began. But others would hesitate, and ask whether faster approvals equal better outcomes? Obviously, it’s a balance, one that regulators understandably struggle with. The FDA has been concentrating on speed, especially for cancer drugs.

Jul 11, 2024 | thelancet.com | Kristina Jenei

Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis - The Lancet Oncology

Apr 1, 2024 | bmjoncology.bmj.com | Kristina Jenei

In pursuit of parity: addressing gender disparities in global cancer research Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Dec 18, 2023 | jclinepi.com | Thomas Piggott |Lorenzo Moja |Kristina Jenei |Tamara Kredo |Nicole Skoetz |Rita Banzi | +10 more

Introduction Guidelines and essential medicine lists (EMLs) bear similarities and differences in the process that lead to decisions. Access to essential medicines is central to achieve to universal health coverage. The World Health Organization (WHO) EML has guided prioritization of essential medicines globally for nearly 50 years, and national EMLs (NEMLs) exist in over 130 countries. Guideline and EML decisions, at WHO or national levels, are not always coordinated and aligned.

Oct 16, 2023 | bmjopen.bmj.com | Kristina Jenei |Daniel Meyers

DiscussionWe sought to examine characteristics of clinicians consulted in Canadian cancer drug funding decisions from 2016 to 2020. We examined clinician recommendations and supporting evidence for the cancer drugs under review for reimbursement. Further, we explored the extent of FCOIs disclosed in clinician submissions and their association with recommending drugs with meaningful clinical benefit.